Clinical Trial Update: Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial exploring the combination of anlotinib and everolimus as first-line treatment for advanced non-clear cell renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• Everolimus (everolimus)

Snippet

Sponsor: Fudan University | Conditions: Renal Cell Carcinoma | Phase 2 | Status: UNKNOWN